GlassScriptPhysician profile
Scott C Oliver
NPI 1316922446
$16,297.48
in general payments reported to CMS, 2019-2025
23 companies · $716 in 2025
The $716 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,872 · 2020: $11K · 2021: $581 · 2022: $965 · 2023: $857 · 2024: $520 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,093.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $11,543.56 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $1,400.85 | 2019 | |
| Alcon Vision LLC | $574.77 | 2021-2025 | Rocklatan, Rhopressa, Total30 |
| Tarsus Pharmaceuticals, INC. | $338.40 | 2024-2025 | Xdemvy |
| Abbvie INC. | $314.99 | 2022-2025 | |
| Optos, INC. | $307.78 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $283.89 | 2019-2021 | |
| Allergan, INC. | $211.63 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $201.68 | 2022-2025 | Envista Aspire Iol, Vyzulta |
| Johnson & Johnson Vision Care, INC. | $164.15 | 2023 | Acuvue |
| Sun Pharmaceutical Industries INC. | $161.57 | 2019-2024 | |
| Oyster Point Pharma, INC. | $142.60 | 2022-2024 | Tyrvaya, Ryzumvi |
| Astellas Pharma US INC | $121.89 | 2024 | Izervay |
| Maculogix, INC. | $109.43 | 2021 | |
| Lkc Technologies, INC. | $88.49 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $64.20 | 2022 | |
| Harrow Eye, LLC | $56.64 | 2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $42.69 | 2021 | |
| Dompe US, INC. | $42.67 | 2020-2023 | Oxervate |
| Carl Zeiss Meditec USA, INC. | $40.91 | 2021 | |
| Eyevance Pharmaceuticals LLC | $28.72 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $28.66 | 2019-2021 | |
| Shire North American Group INC | $27.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Oliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.